Fund VI will focus on investments in industrials and healthcare businesses with proven technologies and solutions positioned to deliver high performance and value-add to their customers
Bharat Swasth Mahotsav organises ‘Padma Doctors Congregation’ for Celebrating Healthcare Changemakers in India Since Independence
75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
Therapy recently approved in Canada under the brand name KORSUVA
Subscribe To Our Newsletter & Stay Updated
